abstract |
(57) The present invention provides a compound of the formula (I): [Wherein, R 2 is an optionally substituted 5,6,7,8-tetrahydronaphth-1-yl group (the remaining groups are as defined in the present application)], Pharmaceutical compositions comprising the compounds and methods of using the compounds for the treatment of conditions where antagonism of the NM1 and / or NK2 receptor is beneficial. |